| Completely intrafascial group | Conventional interfascial group | P value |
---|---|---|---|
No. clinical T stage (%) | Â | Â | 0.735 |
 T1 | 3 (15.0) | 3 (12.5) |  |
 T2 | 12 (60.0) | 17 (70.8) |  |
 T3 | 5 (25.0) | 4 (16.7) |  |
No. clinical N stage (%) | Â | Â | 0.261 |
 N0 | 16 (80.0) | 22 (91.7) |  |
 N+ | 4 (20.0) | 2 (8.3) |  |
No. pathological T stage (%) | Â | Â | 0.785 |
 T0 | 1 (5.0) | 2 (8.3) |  |
 Ta/Tis | 0 (0) | 0 (0) |  |
 T1 | 1 (5.0) | 0 (0) |  |
 T2 | 7 (35.0) | 9 (37.5) |  |
 T3 | 8 (40.0) | 8 (33.3) |  |
 T4 | 3 (15.0) | 5 (20.8) |  |
No. pathological N stage (%) | Â | Â | 0.813 |
 N0 | 14 (70.0) | 16 (66.7) |  |
 N1 | 6 (30.0) | 8 (33.3) |  |
No. positive surgical margins (%) | 5 (25.0) | 3 (12.5) | 0.284 |
No. incidental prostate cancer (%) | 2 (10.0) | 1 (4.2) | 0.445 |
No. local recurrence (%) | 2 (10.0) | 3 (12.5) | 0.795 |
No. metastatic disease (%) | 2 (10.0) | 7 (29.2) | 0.117 |